Clinical trials
Muscle Invasive Bladder Urothelial Carcinoma clinical trials
Below are recruiting muscle invasive bladder urothelial carcinoma clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Little Rock, ArkansasAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Birmingham, AlabamaAges 18 years+ - NCT07480356RecruitingPhase 3
Testing a new bladder cancer treatment (TARA-002) vs standard chemo
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Queen Creek, ArizonaAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Fayetteville, ArkansasAges 18 years+ - NCT05126472RecruitingPhase 1/Phase 2
Study of 2141-V11 for bladder cancer that did not respond to standard treatment
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07187635Recruiting
Urine DNA test before a second bladder tumor surgery
This trial studies if a urine test for tumor DNA can help decide when a second surgery is needed for early stage bladder cancer. It may reduce unnecessary procedures for some patients.
Nanchang, AnhuiAges 18 years+ - NCT07726602Recruiting
Tumor DNA blood test for muscle-invasive bladder cancer
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
Portland, OregonAges 18 years+ - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT07756437Recruiting
Blood test for detecting bladder cancer DNA
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
Ghent, East FlandersAges 18 years+ - NCT06809140RecruitingPhase 2
Bladder-sparing treatment for muscle-invasive bladder cancer
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Duarte, CaliforniaAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT06290687RecruitingPhase 2
Partial cystectomy with chemo for bladder cancer
This trial tests whether removing part of the bladder (partial cystectomy) along with standard chemotherapy or immunotherapy before surgery is effective for people with a specific type of bladder cancer that hasn't spread beyond the bladder.
Cleveland, OhioAges 19 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT06378242RecruitingPhase 1/Phase 2
Testing a bladder cancer drug for high-risk NMIBC patients
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
Guangzhou, GuangdongAges 18–75 - NCT06124976RecruitingPhase 2/Phase 3
A new treatment for low-grade kidney/ureter cancer (ST-02)
This trial tests a new treatment called ST-02 that is given directly into the kidney or ureter to destroy low-grade cancer cells without surgery. It may be an option for people whose cancer has not spread and who are looking for a less invasive treatment.
Vancouver, British ColumbiaAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide study for early bladder cancer in men
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
Tucson, ArizonaAges 18 years+ - NCT05203913RecruitingPhase 2
Bladder cancer trial adds chemo, immunotherapy, and radiation after surgery
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
RomaAges 18 years+ - NCT06204614Enrolling by invitationEarly Phase 1
Drug screening for bladder cancer before surgery
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
Boston, MassachusettsAges 18–120 - NCT06257017RecruitingPhase 2
Using DNA tests to guide chemotherapy after bladder cancer surgery
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
Hong Kong, Hong KongAges 18–70 - NCT06766266RecruitingPhase 1
Irinotecan and Epirubicin for recurring bladder cancer
This trial tests a combination of two chemotherapy drugs (irinotecan and epirubicin) for people whose bladder cancer has come back after prior treatment with a similar drug. The goal is to see if this combination can help shrink or control the cancer.
ChongqingAges 18 years+ - NCT05833867RecruitingPhase 1
Bladder cancer trial combining radiation and Sacituzumab
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
Cleveland, OhioAges 18 years+
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Muscle Invasive Bladder Urothelial Carcinoma trials by city
Studies with a site in or near these metro areas.
Muscle Invasive Bladder Urothelial Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for muscle invasive bladder urothelial carcinoma?
- Yes. Clin2 currently lists 113 recruiting muscle invasive bladder urothelial carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscle invasive bladder urothelial carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscle invasive bladder urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Muscle-Invasive Bladder Carcinoma
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Muscle Invasive Bladder Cancer
- Urothelial Carcinoma Bladder
- Muscle Invasive Bladder Cancer (MIBC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.